论文部分内容阅读
表皮生长因子受体(epidermal growth factor receptor,EGFR)抑制剂是多种恶性实体肿瘤的治疗手段,它不仅为肿瘤患者争取了更长的生存时间,还改善了恶性肿瘤患者的生存质量.随着越来越多的EGFR抑制剂药物的问世,EGFR抑制剂所致皮肤毒副反应的治疗已成为临床工作中极为常见的问题.但目前EGFR抑制剂相关皮肤损害的病理生理、不良反应分级、治疗缺乏统一的标准,并未形成成熟的治疗方案.该文总结梳理了近年来表皮生长因子受体抑制剂相关皮肤毒性的研究现况.“,”Epidermal growth factor receptor (EGFR) inhibitor is a new therapeutic method for several malignant solid tumors,which can not only fight for a longer survival time for cancer patients,but also improve the survival quality of patients with malignant tumors.With the application of more and more EGFR inhibitors in clinical practice,how to treat the EGFR inhibitors related skin toxicity effectively has become a common issue.However,the pathophysiology,grading,and treatment of EGFR inhibitor related skin lesions are lack of uniform standards and mature therapeutic schedules.This paper summarizes the recent researches focusing on EFGR inhibitor related skin toxicity,in order to give some advice on the management of this issue.